Letters Overspending on cancer drug vials

The drug industry can help reduce cancer drug costs

BMJ 2016; 352 doi: http://dx.doi.org/10.1136/bmj.i1551 (Published 21 March 2016) Cite this as: BMJ 2016;352:i1551
  1. Peter J Gilbar, consultant pharmacist and senior lecturer1 2,
  2. Margot J Tannock, senior pharmacist1
  1. 1Cancer and Palliative Care Services, Toowoomba Hospital, Toowoomba, Qld 4350, Australia
  2. 2School of Medicine, University of Queensland, Qld, Australia
  1. peter.gilbar{at}health.qld.gov.au

Bach and colleagues’ article is particularly relevant because cancer drug expenditure is of major concern.1 Increasing the range of vial strengths is one way to contain spending. Unfortunately vial sharing is not always feasible. In Australia, many cancer centres outsource cancer drug manufacturing to accredited commercial suppliers, who, for high …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe